JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jazz Pharmaceuticals PLC (JAZZ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is supported by strong financial growth, positive analyst ratings, and a bullish technical setup. While insider selling is a concern, the company's growth potential and undervaluation make it a compelling long-term investment.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 54.712, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 199.77 with resistance levels at 205.561 and 209.139, suggesting potential upside.
Analysts consistently rate the stock as Overweight or Buy, with price targets ranging from $220 to $275, indicating significant upside potential.
Strong financial performance in Q4 2025, with revenue up 10.09% YoY and net income up 6.45% YoY.
Upcoming Q1 2026 earnings report and webcast could provide further positive momentum.
Insider selling has increased by 385.47% over the last month, which could indicate caution among company insiders.
Gross margin dropped slightly to 73.01%, down -0.76% YoY, which may raise concerns about cost management.
In Q4 2025, Jazz Pharmaceuticals demonstrated strong financial growth: Revenue increased by 10.09% YoY, net income rose by 6.45% YoY, and EPS grew by 7.07% YoY. However, gross margin declined slightly to 73.01%, down -0.76% YoY.
Analysts are highly positive on JAZZ, with multiple firms raising price targets recently. Targets range from $220 to $275, with analysts citing undervaluation, strong growth potential, and visibility into future revenue streams. The stock is seen as a strong buy by most analysts.
